PTC Therapeutics
Develops rare-disease medicines spanning PKU, DMD, gene therapy, and RNA-splicing programs.
$70.59
After-hours close+0.51 (+0.73%)
At close$70.08(−2.41%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 129.03%Insiders 3.06%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 83.46M · Float 73.66M · 88.3% free float
Institutions13F, as of Jun 30, 2026
391 holders · 107.69M shares · 76 new positions · 217 increased · 113 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.96M | 16.73% | +1.02M | Aug 7, 2026 |
| RTW Investments, LP | 7.75M | 9.28% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 7.24M | 8.67% | +7.24Mnew | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.93M | 5.90% | +123.5K | Aug 13, 2026 |
| State Street Corp | 4.60M | 5.51% | +252.4K | Aug 7, 2026 |
| Wellington Management Group LLP | 4.13M | 4.95% | +185.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.74M | 4.48% | +62.9K | Aug 13, 2026 |
| Geode Capital Management, LLC | 2.21M | 2.64% | −2.6K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.80% | 11.90M | 13G | Dec 4, 2025 ↗ |
| Janus Henderson Group PLC | 8.70% | 7.19M | 13G | May 15, 2026 ↗ |
| Armistice Capital, LLC | 6.86% | 5.43M | 13G | May 15, 2025 ↗ |
| Vanguard Portfolio Management | 5.88% | 4.87M | 13G | Apr 29, 2026 ↗ |
| State Street Corporation | 5.20% | 4.21M | 13G | Feb 9, 2026 ↗ |
| Vanguard Capital Management | 5.17% | 4.28M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael Schmertzler | director | 1.50M | 1.80% | Aug 28, 2026 |
| Matthew B. Klein | director, officer: CHIEF EXECUTIVE OFFICER | 383.9K | 0.46% | Aug 6, 2026 |
| Mark Elliott Boulding | officer: EXEC. VP AND CLO | 105.3K | 0.13% | Aug 19, 2026 |
| Pierre Gravier | officer: CHIEF FINANCIAL OFFICER | 84.0K | 0.10% | Jul 16, 2026 |
| Lee Scott Golden | officer: EVP & CHIEF MEDICAL OFFICER | 79.1K | 0.09% | Apr 6, 2026 |
| Eric Pauwels | officer: CHIEF BUSINESS OFFICER | 73.4K | 0.09% | Jun 12, 2026 |
| Christine Marie Utter | officer: SVP, CHIEF ACCOUNTING OFFICER | 70.2K | 0.08% | Jun 22, 2026 |
| Neil Gregory Almstead | officer: CHIEF TECHNICAL OPS OFFICER | 63.0K | 0.08% | Jul 13, 2026 |
| Hege Elisabeth Sollie-Zetlmayer | director | 46.5K | 0.06% | Jul 30, 2026 |
| Jerome B. Zeldis | director | 22.5K | 0.03% | Jan 6, 2026 |
2 ten-percent owners hold 2.72M shares by Form 4, outside the officers-and-directors figure above · 16 people have not refiled in the last 18 months (1.48M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 27, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $71.58 | 1,336,594 |
| Aug 26, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $72.94 | 1,349,094 |
| Aug 20, 2026 | Michael Schmertzlerdirector | Sale · 3 lots | 12,500 | $71.11 | 1,361,594 |
| Aug 19, 2026 | Michael Schmertzlerdirector | Sale · 2 lots | 12,500 | $73.32 | 1,374,094 |
| Aug 17, 2026 | Mark Elliott Bouldingofficer: EXEC. VP AND CLO | Sale · 2 lots | 2,813 | $72.57 | 105,272 |
| Aug 4, 2026 | Matthew B. Kleindirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 10,292 | $68.57 | 383,868 |
| Jul 14, 2026 | Pierre Gravierofficer: CHIEF FINANCIAL OFFICER | Sale | 3,494 | $80.35 | 83,986 |
| Jul 9, 2026 | Neil Gregory Almsteadofficer: CHIEF TECHNICAL OPS OFFICER | Sale | 2,464 | $90.25 | 60,299 |
| Jul 9, 2026 | Mary L. Smithdirector | Sale | 5,834 | $90.00 | 21,813 |
| Jul 6, 2026 | Neil Gregory Almsteadofficer: CHIEF TECHNICAL OPS OFFICER | Sale · 5 lots | 22,161 | $86.00 | 60,299 |
CongressHouse and Senate disclosures
Not reported.